NCT04308330 2026-04-15
NYMC195
New York Medical College
Phase 1 Recruiting
Clinical Trials
10 trialsNCT02559778 2026-02-20
PEDS-PLAN
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT07261241 2025-12-03
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Not yet recruiting
NCT03332667 2025-04-16
MIBG With Dinutuximab +/- Vorinostat
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT01019850 2023-04-10
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT03561259 2023-02-16
OPTIMUM
Jubilant DraxImage Inc.
Phase 2 Unknown
NCT02035137 2022-06-08
N2011-01
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Completed
NCT01132911 2017-07-02
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01208454 2015-11-24
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00217412 2014-06-17
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
National Cancer Institute (NCI)
Phase 1 Completed